The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Advances Day 2017 | Risks and treatments for pregnant MPN patients
Though women of childbearing age are diagnosed with myeloproliferative neoplasms (MPNs) less frequently than the general population, it is key that all hematologists are aware of the treatment options available to women with MPNs who are planning to become pregnant or are already pregnant, and work with the patient’s obstetrician and midwifery group to maximize the chance of a healthy birth. In this interview, Susan Robinson, MBBS, MCRP, MDRes, FRCP, FRCPath, from Guy’s and St Thomas’ Hospital NHS Foundation Trust, London, UK, discusses the statistics and risks regarding pregnancy in patients with MPNs, the treatments and precautions typically taken, and how future studies can improve treatment strategies further. This video was recorded at the Myeloproliferative Neoplasms Advances Day 2017, held in London, UK.
